RenovoRx, Inc. (RNXT): Price and Financial Metrics
GET POWR RATINGS... FREE!
RNXT Stock Price Chart Interactive Chart >
RNXT Price/Volume Stats
| Current price | $2.63 | 52-week high | $5.00 |
| Prev. close | $2.61 | 52-week low | $1.50 |
| Day low | $2.57 | Volume | 9,733 |
| Day high | $2.68 | Avg. volume | 67,557 |
| 50-day MA | $2.36 | Dividend yield | N/A |
| 200-day MA | $2.10 | Market Cap | 23.86M |
RenovoRx, Inc. (RNXT) Company Bio
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.
Latest RNXT News From Around the Web
Below are the latest news stories about RENOVORX INC that investors may wish to consider to help them evaluate RNXT as an investment opportunity.
RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023LOS ALTOS, Calif., January 25, 2023--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that Shaun Bagai, Chief Executive Officer, is scheduled to present virtually at the Sequire Biotechnology Conference on Thursday, February 2, 2023 at 4 p.m. (ET). To register for the event, visit the Sequire Biotechnology Conference website. |
RenovoRx Reports Initial Results From Targeted Treatment For Pancreatic CancerRenovoRx Inc (NASDAQ: RNXT) announced initial results from a pharmacokinetic (PK) substudy within the phase 3 un-blinded randomized control TIGeR-PaC clinical trial to be presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium this week. The TIGeR-PaC clinical trial is evaluating intra-arterial (IA) administration of gemcitabine (chemotherapy) using the proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) platform for targeted treatment of Locally Advanced Pancreatic |
RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer TreatmentLOS ALTOS, Calif., January 18, 2023--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced initial results from a pharmacokinetic (PK) substudy within the phase III un-blinded randomized control TIGeR-PaC clinical trial to be presented at the 2023 ASCO Gastrointestinal (ASCO GI) Cancers Symposium this week. The TIGeR-PaC clinical trial is evaluating intra-arterial (IA) administration of gemcitabine (chemotherapy) using the |
Here's Why RenovoRx (NASDAQ:RNXT) Must Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US PatentLOS ALTOS, Calif., January 05, 2023--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced that on January 3, 2023 the United States Patent and Trademark Office issued US patent number 11,541,211 broadly covering methods for treating cholangiocarcinoma (bile duct cancer) by selectively delivering one or more therapeutic agents into targeted regions of the bile duct. This is RenovoRx’s eighth US patent. |
RNXT Price Returns
| 1-mo | 11.91% |
| 3-mo | 49.43% |
| 6-mo | 35.57% |
| 1-year | -20.78% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 11.91% |
| 2022 | -51.45% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...